[go: up one dir, main page]

MX2022016455A - Derivados de sulfona. - Google Patents

Derivados de sulfona.

Info

Publication number
MX2022016455A
MX2022016455A MX2022016455A MX2022016455A MX2022016455A MX 2022016455 A MX2022016455 A MX 2022016455A MX 2022016455 A MX2022016455 A MX 2022016455A MX 2022016455 A MX2022016455 A MX 2022016455A MX 2022016455 A MX2022016455 A MX 2022016455A
Authority
MX
Mexico
Prior art keywords
formula
present
sulphone derivatives
compounds
sulphone
Prior art date
Application number
MX2022016455A
Other languages
English (en)
Inventor
Wolfgang Haap
Luke Green
Buelent Kocer
Claus Riemer
Andreas Kuglstatter
Andrew Simon Bell
Patrizio Mattei
Jérémy BESNARD
Anthony Richard Bradley
Xavier Lucas
Dmitry Mazunin
Hoorn Willem Paul Van
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2022016455A publication Critical patent/MX2022016455A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona compuestos de Fórmula I (ver Fórmula) (I) en donde X1, X2, X3, X4, R1, R1a, R1b, R2', R2", R3', R3", R6 y R7 son como se describe en la presente descripción, así como también sus sales aceptables desde el punto de vista farmacéutico. Además, la presente invención se refiere a la fabricación de compuestos de Fórmula I, composiciones farmacéuticas que los comprenden y su uso como medicamentos.
MX2022016455A 2020-06-22 2021-06-21 Derivados de sulfona. MX2022016455A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20181363 2020-06-22
PCT/EP2021/066767 WO2021259831A1 (en) 2020-06-22 2021-06-21 Sulfone derivatives

Publications (1)

Publication Number Publication Date
MX2022016455A true MX2022016455A (es) 2023-02-01

Family

ID=71120071

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016455A MX2022016455A (es) 2020-06-22 2021-06-21 Derivados de sulfona.

Country Status (18)

Country Link
US (1) US20230219953A1 (es)
EP (1) EP4168392A1 (es)
JP (1) JP7731381B2 (es)
KR (1) KR20230026479A (es)
CN (1) CN115916756A (es)
AR (1) AR122705A1 (es)
AU (1) AU2021294933A1 (es)
BR (1) BR112022026105A2 (es)
CA (1) CA3187145A1 (es)
CL (1) CL2022003677A1 (es)
CO (1) CO2023000117A2 (es)
CR (1) CR20220644A (es)
IL (1) IL298824A (es)
MX (1) MX2022016455A (es)
PE (1) PE20230838A1 (es)
TW (1) TWI812966B (es)
WO (1) WO2021259831A1 (es)
ZA (1) ZA202213430B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117430596A (zh) * 2022-07-13 2024-01-23 上海海和药物研究开发股份有限公司 二并环类mat2a抑制剂及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005323311A1 (en) * 2004-11-23 2006-07-13 Venkateswara Rao Batchu Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them
AU2010224693B2 (en) 2009-03-19 2016-07-28 Lifearc Compounds
WO2011068211A1 (ja) 2009-12-04 2011-06-09 大正製薬株式会社 ２－ピリドン化合物
WO2011138751A2 (en) 2010-05-04 2011-11-10 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
RU2012154308A (ru) 2010-05-17 2014-06-27 Эррэй Биофарма Инк. Пиперидинил-замещенные лактамы как модуляторы gpr119
EP2693880A1 (en) 2011-04-04 2014-02-12 Merck Sharp & Dohme Corp. Gamma secretase inhibitors
EP2750678B1 (en) 2011-08-29 2017-03-22 PTC Therapeutics, Inc. Antibacterial compounds and methods for use
WO2013130855A1 (en) * 2012-03-02 2013-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
MX2015005506A (es) 2012-11-08 2015-08-05 Pfizer Compuestos heteroaromaticos como ligandos d1 de dopamina.
CA2921880A1 (en) 2013-08-22 2015-02-26 F. Hoffmann-La Roche Ag Alkynyl alcohols and methods of use
KR102602947B1 (ko) * 2014-11-03 2023-11-16 아이오메트 파마 엘티디 제약 화합물
WO2018011628A1 (en) 2016-07-11 2018-01-18 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
CN119528824A (zh) * 2018-12-10 2025-02-28 伊迪亚生物科学有限公司 2-氧代喹唑啉衍生物作为甲硫氨酸腺苷转移酶2a抑制剂
CN113474347A (zh) * 2018-12-27 2021-10-01 法国施维雅药厂 Mat2a的aza杂双环抑制剂和用于治疗癌症的方法

Also Published As

Publication number Publication date
BR112022026105A2 (pt) 2023-01-17
CN115916756A (zh) 2023-04-04
CL2022003677A1 (es) 2023-07-28
PE20230838A1 (es) 2023-05-19
EP4168392A1 (en) 2023-04-26
CR20220644A (es) 2023-02-17
KR20230026479A (ko) 2023-02-24
CO2023000117A2 (es) 2023-04-27
IL298824A (en) 2023-02-01
AR122705A1 (es) 2022-09-28
JP2023531020A (ja) 2023-07-20
US20230219953A1 (en) 2023-07-13
JP7731381B2 (ja) 2025-08-29
CA3187145A1 (en) 2021-12-30
AU2021294933A1 (en) 2023-02-02
TWI812966B (zh) 2023-08-21
TW202208361A (zh) 2022-03-01
WO2021259831A1 (en) 2021-12-30
ZA202213430B (en) 2023-08-30

Similar Documents

Publication Publication Date Title
CL2022002386A1 (es) Compuestos de amino pirimidina fusionados
CL2021001396A1 (es) Derivados de panteteína y usos de los mismos
ECSP10010178A (es) Derivados bis-(sulfonilamino) en terapia 066
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
UY31546A1 (es) Derivados bis-(sulfonilamino) en terapia 205
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
CL2022003646A1 (es) Derivados de amidopirimidona
ECSP23070418A (es) Moduladores de sting (estimulador de genes de interferón)
UY30617A1 (es) Derivados sustituidos del carbamato de 1-(9-{[(2r)-2-{4-hidroxi-3-[(metilsulfonil)amino]fenil}etil]amino}nonil)piperidin-4-ilo, sus sales y solvatos farmacéuticamente aceptables y aplicaciones
ECSP22020159A (es) Derivados de piridazin-3(2h)-ona fusionados con azol
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CL2020001817A1 (es) Moduladores del receptor c5a
UY28547A1 (es) Derivados de disulfuro, sulfuro, sulfóxido y sulfona de azúcares cíclicos y sus usos.
CL2021002480A1 (es) Agonistas compuestos macrocíclicos como de sting
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
UY30363A1 (es) Derivados sustituidos de la n-(3-oxo-2,3-dihidro-1h-isoindol-4-il)-1-naftamida, procesos de preparacion, composiciones farmacéuticas y aplicaciones
PA8589801A1 (es) Aminoalcoxiindoles
UY28357A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparación de los mismos y sus usos
CO2023000117A2 (es) Derivados de sulfona
CO2022015823A2 (es) Derivados de n-(piperidin-4-il)benzamida de acción luminal
UY29134A1 (es) Sulfonamidas sustituidas por derivados de bencimidazol, composiciones que la contienen, procedimiento de preparacion y aplicaciones
UY28715A1 (es) Derivados de diarilmetil piperazina, sus preparaciones y sus usos
CL2023002052A1 (es) Derivados de pirazolamida
UY29394A1 (es) Derivados sustituidos de n-(5-(2-propilamino.1.hidroxietil)-2-hdroxifenil) metano sulfonamida, composiciones farmacéuticas que lo contienen y aplicaciónes.